Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Cash from Operations (2016 - 2025)

Historic Cash from Operations for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to -$236987.0.

  • China Pharma Holdings' Cash from Operations fell 40474.31% to -$236987.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $201107.0, marking a year-over-year increase of 12765.65%. This contributed to the annual value of -$500000.0 for FY2024, which is 2853.94% up from last year.
  • Latest data reveals that China Pharma Holdings reported Cash from Operations of -$236987.0 as of Q3 2025, which was down 40474.31% from $293258.0 recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' Cash from Operations peaked at $1.0 million during Q3 2023, and registered a low of -$1.5 million during Q1 2023.
  • Over the past 5 years, China Pharma Holdings' median Cash from Operations value was -$72726.0 (recorded in 2024), while the average stood at -$98042.0.
  • As far as peak fluctuations go, China Pharma Holdings' Cash from Operations soared by 101760.07% in 2024, and later crashed by 40474.31% in 2025.
  • Over the past 5 years, China Pharma Holdings' Cash from Operations (Quarter) stood at -$198112.0 in 2021, then soared by 395.08% to $584594.0 in 2022, then crashed by 103.82% to -$22323.0 in 2023, then surged by 1017.6% to $204836.0 in 2024, then plummeted by 215.7% to -$236987.0 in 2025.
  • Its Cash from Operations was -$236987.0 in Q3 2025, compared to $293258.0 in Q2 2025 and -$60000.0 in Q1 2025.